40 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
currently serves as the Chief Commercial Officer of Grünenthal and previously spent two decades in roles of increasing responsibility at Novartis … , fiduciary responsibility.
Each of the individuals nominated for appointment or re-appointment to the Board of Directors were approved for such nomination
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
responsibility for any approved product covered by Medicare Part D could be significantly greater under the newly designed Part D benefit structure
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
of Grünenthal and previously spent two decades in roles of increasing responsibility at Novartis, ultimately serving on the Pharma Executive Committee … and image, time available for meetings and consultation on our matters and willingness to assume broad, fiduciary responsibility.
Each of the individuals
424B3
NAMS
NewAmsterdam Pharma Company NV
19 Apr 24
Prospectus supplement
4:21pm
. Neither we nor TD Cowen take responsibility for, or provide assurance as to the reliability of, any other information that others may give you
POS AM
NAMS
NewAmsterdam Pharma Company NV
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
responsibility for, or provide assurance as to the reliability of, any other information that others may give you. This prospectus does not constitute an offer … agent of the Company, agent of the trustees or agent of the warrant agents or unit agents will have any responsibility or liability for any aspect
424B3
q8sso3in836n7wpz
12 Mar 24
Prospectus supplement
4:18pm
POS AM
kgn99f0zozu7kvg9
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
10-K
ai779bkkrs5
28 Feb 24
Annual report
8:00am
8-K
EX-1.1
et0u mcnc
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
424B5
rq2ij
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
zvbc3py4x6 hf8ub
13 Feb 24
Prospectus supplement for primary offering
5:19pm
424B3
hgu kg04mmnu85
19 Dec 23
Prospectus supplement
4:36pm
F-3
EX-1.2
c418g676 bd
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
EX-4.1
23c7 5uga
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
EX-4.2
3frcn
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
cq19yi2 hge
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
vbvk7 7wo9ywt2
15 Aug 23
Prospectus supplement
4:52pm
6-K
EX-99.1
k7w jer5dt1sgq1
14 Aug 23
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
4:52pm
POS AM
p52mqnm709 09wqsg0
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
fpacs8d 3j3isge2873t
7 Aug 23
Research and development expenses
7:24am